<p>M.E. Allison &amp; CO. Inc. 在第二季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 44.5%，根据其最近向证券交易委员会提交的 13F 文件。该基金在季度内额外购买了 11,186 股后，持有该生物制药公司 36,348 股股票。根据其最近向证券交易委员会提交的文件，M.E. Allison &amp; CO. Inc. 在辉瑞的持股价值为 881,000 美元。</p>
<ul>
<li>MarketBeat 周报 – 10/06 - 10/10</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也买卖了该公司的股票。贝斯默集团（Bessemer Group Inc.）在第一季度将其在辉瑞的股份提高了 11.1%。贝斯默集团目前持有 132,478 股辉瑞的股票，价值 3,358,000 美元，此前在上个季度额外购买了 13,228 股。Capital Advisors Inc. OK 在第一季度将其在辉瑞的股份提高了 1.2%。Capital Advisors Inc. OK 目前持有 1,413,472 股辉瑞的股票，价值 35,817,000 美元，此前在上个季度额外购买了 17,032 股。丘吉尔管理公司（CHURCHILL MANAGEMENT Corp）在第一季度购买了辉瑞的新股份，价值约为 8,283,000 美元。Westbourne Investments Inc. 在第一季度购买了辉瑞的新股份，价值约为 2,411,000 美元。最后，Bourne Lent Asset Management Inc. 在第二季度将其在辉瑞的股份提高了 90.8%。Bourne Lent Asset Management Inc. 目前持有 38,255 股辉瑞的股票，价值 927,000 美元，此前在上个季度额外购买了 18,200 股。68.36% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>多位分析师对 PFE 股票发表了评论。瑞银集团（UBS Group）在 10 月 1 日的研究报告中重申了对辉瑞的 “中性” 评级，并设定了 28.00 美元的目标价格。摩根士丹利（Morgan Stanley）在周五的研究报告中将辉瑞的目标价格从 33.00 美元下调至 32.00 美元，并对该公司设定了 “等权重” 评级。韦斯评级（Weiss Ratings）在 10 月 8 日的研究报告中重申了对辉瑞的 “持有（c-）” 评级。美国银行（Bank of America）在 10 月 3 日的研究报告中将辉瑞的目标价格从 28.00 美元提高至 30.00 美元，并给予该股票 “中性” 评级。最后，Wall Street Zen 在 9 月 28 日的研究报告中将辉瑞的评级从 “买入” 下调至 “持有”。两位股票研究分析师对该股票给予了强烈买入评级，四位给予了买入评级，十二位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 28.35 美元。</p>
<ul>
<li>5 个医疗保健股票推动行业的大反弹</li>
</ul>
<p><strong>查看我们关于辉瑞的最新研究报告</strong></p>
<h2>辉瑞股价下跌 1.7%</h2>
<p>辉瑞股票周一开盘价为 24.81 美元。辉瑞公司 12 个月低点为 20.92 美元，12 个月高点为 29.82 美元。该公司的速动比率为 0.85，流动比率为 1.16，债务与股本比率为 0.65。该公司的 50 日移动平均线为 24.86 美元，200 日移动平均线为 24.12 美元。该公司的市值为 1410.3 亿美元，市盈率为 13.19，市盈增长比率为 0.82，贝塔值为 0.55。</p>
<ul>
<li>为什么 AbbVie 和强生可能会超越辉瑞</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 8 月 5 日宣布了其季度财报。这家生物制药公司报告本季度每股收益为 0.78 美元，超出市场共识预期的 0.58 美元，超出 0.20 美元。辉瑞的股本回报率为 21.42%，净利润率为 16.84%。该公司本季度的收入为 146.5 亿美元，而市场共识预期为 134.3 亿美元。去年同期，该公司的每股收益为 0.60 美元。与去年同期相比，该公司的季度收入增长了 10.3%。辉瑞已将其 2025 财年的指引设定为 2.900-3.100 每股收益。股票分析师预测辉瑞公司今年将发布 2.95 每股收益。</p>
<h2>辉瑞分红公告</h2>
<p>该公司最近还披露了一项季度分红，将于 12 月 1 日（星期一）支付。11 月 7 日（星期五）的股东将获得 0.43 美元的分红。除息日期为 11 月 7 日（星期五）。这代表着每年 1.72 美元的分红和 6.9% 的分红收益率。辉瑞的分红支付比率（DPR）目前为 91.49%。</p>
<h2>辉瑞简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过辉瑞</li>
<li>制造业股票投资</li>
<li>Microsoft 365 Premium 标志着 AI 变现的下一个阶段</li>
<li>期权交易 - 理解行使价格</li>
<li>Target 的折扣周是否会为投资者带来回报？</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>在财报发布前购买 Sprouts Farmers Market 的三个理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>M.E. Allison & CO. Inc. 在第二季度将其在辉瑞公司（NYSE:PFE）的持股增加了 44.5%，目前拥有 36,348 股，价值为 881,000 美元。其他机构投资者也调整了他们的持股。分析师对辉瑞的评级意见不一，普遍评级为 “持有”，平均目标价为 28.35 美元。辉瑞的股票开盘价为 24.81 美元，市值为 1410.3 亿美元。该公司报告第二季度每股收益为 0.78 美元，超出预期，并宣布季度股息为 0.43 美元，将于 12 月 1 日支付</p>

<p>M.E. Allison &amp; CO. Inc. raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 44.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,348 shares of the biopharmaceutical company's stock after acquiring an additional 11,186 shares during the quarter. M.E. Allison &amp; CO. Inc.'s holdings in Pfizer were worth $881,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>M.E. Allison &amp; CO. Inc. 在第二季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 44.5%，根据其最近向证券交易委员会提交的 13F 文件。该基金在季度内额外购买了 11,186 股后，持有该生物制药公司 36,348 股股票。根据其最近向证券交易委员会提交的文件，M.E. Allison &amp; CO. Inc. 在辉瑞的持股价值为 881,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 10/06 - 10/10</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 10/06 - 10/10</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Bessemer Group Inc. lifted its stake in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK lifted its stake in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in Pfizer during the first quarter valued at about $8,283,000. Westbourne Investments Inc. purchased a new stake in Pfizer during the first quarter valued at about $2,411,000. Finally, Bourne Lent Asset Management Inc. lifted its stake in Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after buying an additional 18,200 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也买卖了该公司的股票。贝斯默集团（Bessemer Group Inc.）在第一季度将其在辉瑞的股份提高了 11.1%。贝斯默集团目前持有 132,478 股辉瑞的股票，价值 3,358,000 美元，此前在上个季度额外购买了 13,228 股。Capital Advisors Inc. OK 在第一季度将其在辉瑞的股份提高了 1.2%。Capital Advisors Inc. OK 目前持有 1,413,472 股辉瑞的股票，价值 35,817,000 美元，此前在上个季度额外购买了 17,032 股。丘吉尔管理公司（CHURCHILL MANAGEMENT Corp）在第一季度购买了辉瑞的新股份，价值约为 8,283,000 美元。Westbourne Investments Inc. 在第一季度购买了辉瑞的新股份，价值约为 2,411,000 美元。最后，Bourne Lent Asset Management Inc. 在第二季度将其在辉瑞的股份提高了 90.8%。Bourne Lent Asset Management Inc. 目前持有 38,255 股辉瑞的股票，价值 927,000 美元，此前在上个季度额外购买了 18,200 股。68.36% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of analysts have commented on PFE shares. UBS Group reaffirmed a &#34;neutral&#34; rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an &#34;equal weight&#34; rating for the company in a research note on Friday. Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, October 3rd. Finally, Wall Street Zen lowered shares of Pfizer from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $28.35.</p>
<div class="lb-trans"><p>多位分析师对 PFE 股票发表了评论。瑞银集团（UBS Group）在 10 月 1 日的研究报告中重申了对辉瑞的 “中性” 评级，并设定了 28.00 美元的目标价格。摩根士丹利（Morgan Stanley）在周五的研究报告中将辉瑞的目标价格从 33.00 美元下调至 32.00 美元，并对该公司设定了 “等权重” 评级。韦斯评级（Weiss Ratings）在 10 月 8 日的研究报告中重申了对辉瑞的 “持有（c-）” 评级。美国银行（Bank of America）在 10 月 3 日的研究报告中将辉瑞的目标价格从 28.00 美元提高至 30.00 美元，并给予该股票 “中性” 评级。最后，Wall Street Zen 在 9 月 28 日的研究报告中将辉瑞的评级从 “买入” 下调至 “持有”。两位股票研究分析师对该股票给予了强烈买入评级，四位给予了买入评级，十二位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 28.35 美元。</p>
</div><ul>
<li>5 Healthcare Plays Powering the Sector’s Big Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健股票推动行业的大反弹</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on Pfizer</strong></p>
<div class="lb-trans"><p><strong>查看我们关于辉瑞的最新研究报告</strong></p>
</div><h2>Pfizer Trading Down 1.7%</h2>
<div class="lb-trans"><h2>辉瑞股价下跌 1.7%</h2>
</div><p>Shares of PFE stock opened at $24.81 on Monday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.82. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business's 50 day moving average is $24.86 and its two-hundred day moving average is $24.12. The company has a market cap of $141.03 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.</p>
<div class="lb-trans"><p>辉瑞股票周一开盘价为 24.81 美元。辉瑞公司 12 个月低点为 20.92 美元，12 个月高点为 29.82 美元。该公司的速动比率为 0.85，流动比率为 1.16，债务与股本比率为 0.65。该公司的 50 日移动平均线为 24.86 美元，200 日移动平均线为 24.12 美元。该公司的市值为 1410.3 亿美元，市盈率为 13.19，市盈增长比率为 0.82，贝塔值为 0.55。</p>
</div><ul>
<li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 AbbVie 和强生可能会超越辉瑞</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the company posted $0.60 earnings per share. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 8 月 5 日宣布了其季度财报。这家生物制药公司报告本季度每股收益为 0.78 美元，超出市场共识预期的 0.58 美元，超出 0.20 美元。辉瑞的股本回报率为 21.42%，净利润率为 16.84%。该公司本季度的收入为 146.5 亿美元，而市场共识预期为 134.3 亿美元。去年同期，该公司的每股收益为 0.60 美元。与去年同期相比，该公司的季度收入增长了 10.3%。辉瑞已将其 2025 财年的指引设定为 2.900-3.100 每股收益。股票分析师预测辉瑞公司今年将发布 2.95 每股收益。</p>
</div><h2>Pfizer Dividend Announcement</h2>
<div class="lb-trans"><h2>辉瑞分红公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's dividend payout ratio (DPR) is presently 91.49%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度分红，将于 12 月 1 日（星期一）支付。11 月 7 日（星期五）的股东将获得 0.43 美元的分红。除息日期为 11 月 7 日（星期五）。这代表着每年 1.72 美元的分红和 6.9% 的分红收益率。辉瑞的分红支付比率（DPR）目前为 91.49%。</p>
</div><h2>Pfizer Profile</h2>
<div class="lb-trans"><h2>辉瑞简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Manufacturing Stocks Investing</li>
<li>Microsoft 365 Premium Marks the Next Phase of AI Monetization</li>
<li>Options Trading - Understanding Strike Price</li>
<li>Could Target’s Week of Discounts Come Full Circle for Investors?</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过辉瑞</li>
<li>制造业股票投资</li>
<li>Microsoft 365 Premium 标志着 AI 变现的下一个阶段</li>
<li>期权交易 - 理解行使价格</li>
<li>Target 的折扣周是否会为投资者带来回报？</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>在财报发布前购买 Sprouts Farmers Market 的三个理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pfizer Inc. $PFE Shares Bought by M.E. Allison & CO. Inc.

- M.E. Allison & CO. Inc. 在第二季度增持 Pfizer 44.5%，持股达 36,348 股。  
- Pfizer 第二季度营收为 146.5 亿美元，超出预期，EPS 为 0.78 美元。  
- Pfizer 宣布季度股息为 0.43 美元，股息收益率为 6.9%。  

M.E. Allison & CO. Inc. 购买了辉瑞公司 $PFE 的股票